HAVCR2 and neoplasm: IPI-549 or PD-L1 single or dual treatments did not affect PD-1, CTLA-4, TIGIT, LAG-3, or TIM-3 expression in tumor-infiltrating CD4+ T-cells in HNSCC tumor-bearing mice (Figure 6C–G).